Though we are limited to clinical diagnoses of MCI and AD in ADNI based on cognitive assessments without molecular imaging or neuropathological confirmation, we observed the expected decrease in CSF Aβ and increase in CSF tau in MCI and AD versus controls (ANOVA p-values = 2.68 × 10-14 for Aβ and 0.00083 for tau; data not shown). The gene discussed is MAPT; the disease is Alzheimer disease.